Novel therapeutics for patients with non-muscle-invasive bladder cancer

Robert S. Svatek, Ashish M. Kamat, Colin P. Dinney

Producción científica: Review articlerevisión exhaustiva

10 Citas (Scopus)


A number of novel therapeutics are being developed for non-muscle-invasive bladder cancer (NMIBC). Several of these agents have made their way into clinical trials. NMIBC includes a heterogeneous group of tumors with a wide range of recurrence and progression rates that must be considered in the design of clinical trials for these newer agents. Indeed, the goals of novel therapeutics for NMIBC differ depending on the recurrence and progression risk. The authors discuss the clinical experience with novel therapeutics, including alternative chemotherapeutics (apaziquone, docetaxel and gemcitabine), new paradigms for the delivery of chemotherapy, gene therapy and photodynamic therapy, emphasizing the need for appropriate risk stratification and comparison groups for future trials.

Idioma originalEnglish (US)
Páginas (desde-hasta)807-813
Número de páginas7
PublicaciónExpert Review of Anticancer Therapy
EstadoPublished - 2009
Publicado de forma externa

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology


Profundice en los temas de investigación de 'Novel therapeutics for patients with non-muscle-invasive bladder cancer'. En conjunto forman una huella única.

Citar esto